Read More

WuXi Biologics Announces Research Service Agreement With BioNTech On Discovering Investigational Monoclonal Antibodies For Developing Next-Generation Therapeutic Product Candidates; WuXi Biologics Will Receive A $20M Upfront Payment

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its Research Service Unit (R in CRDMO) has signed a research service

BNTX